Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.

@article{Viney2016AntisenseOT,
  title={Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.},
  author={Nicholas J Viney and Julian C. van Capelleveen and Richard S. Geary and Shuting Xia and Joseph A Tami and Rosie Z. Yu and Santica M. Marcovina and Steven G. Hughes and Mark J. Graham and Rosanne M. Crooke and Stanley T. Crooke and Joseph L. Witztum and Erik Stroes and Sotirios Tsimikas},
  journal={Lancet},
  year={2016},
  volume={388 10057},
  pages={2239-2253}
}
BACKGROUND Elevated lipoprotein(a) (Lp[a]) is a highly prevalent (around 20% of people) genetic risk factor for cardiovascular disease and calcific aortic valve stenosis, but no approved specific therapy exists to substantially lower Lp(a) concentrations. We aimed to assess the efficacy, safety, and tolerability of two unique antisense oligonucleotides designed to lower Lp(a) concentrations. METHODS We did two randomised, double-blind, placebo-controlled trials. In a phase 2 trial (done in 13… CONTINUE READING
Blog posts, news articles and tweet counts and IDs sourced by
Altmetric.com